145 related articles for article (PubMed ID: 15665559)
1. Raf kinase inhibitors in oncology.
Strumberg D; Seeber S
Onkologie; 2005 Feb; 28(2):101-7. PubMed ID: 15665559
[TBL] [Abstract][Full Text] [Related]
2. Raf pathway inhibitors in oncology.
Bollag G; Freeman S; Lyons JF; Post LE
Curr Opin Investig Drugs; 2003 Dec; 4(12):1436-41. PubMed ID: 14763129
[TBL] [Abstract][Full Text] [Related]
3. Raf: a strategic target for therapeutic development against cancer.
Beeram M; Patnaik A; Rowinsky EK
J Clin Oncol; 2005 Sep; 23(27):6771-90. PubMed ID: 16170185
[TBL] [Abstract][Full Text] [Related]
4. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Gollob JA; Wilhelm S; Carter C; Kelley SL
Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
[TBL] [Abstract][Full Text] [Related]
5. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
Roberts PJ; Der CJ
Oncogene; 2007 May; 26(22):3291-310. PubMed ID: 17496923
[TBL] [Abstract][Full Text] [Related]
6. Regulation of c-Raf-1: therapeutic implications.
Beeram M; Patnaik A; Rowinsky EK
Clin Adv Hematol Oncol; 2003 Aug; 1(8):476-81. PubMed ID: 16258435
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
Adnane L; Trail PA; Taylor I; Wilhelm SM
Methods Enzymol; 2006; 407():597-612. PubMed ID: 16757355
[TBL] [Abstract][Full Text] [Related]
8. B-Raf kinase inhibitors for cancer treatment.
Li N; Batt D; Warmuth M
Curr Opin Investig Drugs; 2007 Jun; 8(6):452-6. PubMed ID: 17621874
[TBL] [Abstract][Full Text] [Related]
9. Novel small molecule Raf kinase inhibitors for targeted cancer therapeutics.
Kim DH; Sim T
Arch Pharm Res; 2012 Mar; 35(4):605-15. PubMed ID: 22553052
[TBL] [Abstract][Full Text] [Related]
10. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.
Strumberg D; Clark JW; Awada A; Moore MJ; Richly H; Hendlisz A; Hirte HW; Eder JP; Lenz HJ; Schwartz B
Oncologist; 2007 Apr; 12(4):426-37. PubMed ID: 17470685
[TBL] [Abstract][Full Text] [Related]
11. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic strategies for inhibiting oncogenic BRAF signaling.
Halilovic E; Solit DB
Curr Opin Pharmacol; 2008 Aug; 8(4):419-26. PubMed ID: 18644254
[TBL] [Abstract][Full Text] [Related]
14. Novel mitogen-activated protein kinase kinase inhibitors.
Chapman MS; Miner JN
Expert Opin Investig Drugs; 2011 Feb; 20(2):209-20. PubMed ID: 21235429
[TBL] [Abstract][Full Text] [Related]
15. Raf kinases: oncogenesis and drug discovery.
Schreck R; Rapp UR
Int J Cancer; 2006 Nov; 119(10):2261-71. PubMed ID: 16894562
[TBL] [Abstract][Full Text] [Related]
16. Targeting the RAF-MEK-ERK pathway in cancer therapy.
Montagut C; Settleman J
Cancer Lett; 2009 Oct; 283(2):125-34. PubMed ID: 19217204
[TBL] [Abstract][Full Text] [Related]
17. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.
Friday BB; Adjei AA
Clin Cancer Res; 2008 Jan; 14(2):342-6. PubMed ID: 18223206
[TBL] [Abstract][Full Text] [Related]
18. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors.
Clark JW; Eder JP; Ryan D; Lathia C; Lenz HJ
Clin Cancer Res; 2005 Aug; 11(15):5472-80. PubMed ID: 16061863
[TBL] [Abstract][Full Text] [Related]
19. Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy.
Mandal R; Becker S; Strebhardt K
Oncogene; 2016 May; 35(20):2547-61. PubMed ID: 26364606
[TBL] [Abstract][Full Text] [Related]
20. [Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations].
Boige V; Barbare JC; Rosmorduc O;
Gastroenterol Clin Biol; 2008 Jan; 32(1 Pt. 1):3-7. PubMed ID: 18341970
[No Abstract] [Full Text] [Related]
[Next] [New Search]
